We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+33.86%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$680M
AUM Growth
+$169M
Cap. Flow
+$61.2M
Cap. Flow %
9%
Top 10 Hldgs %
79.62%
Holding
31
New
9
Increased
4
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
OLMA icon
Olema Pharmaceuticals
OLMA
+$72M
2
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$59.1M
3
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$19.5M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$10.2M
5
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
+$9.47M

Top Sells

Rank Stock Value
1
TRIL
Trillium Therapeutics Inc.
TRIL
+$45.6M
2
SURF
Surface Oncology, Inc. Common Stock
SURF
+$21.2M
3
CRDF icon
Cardiff Oncology
CRDF
+$18M
4
IMV
IMV Inc. Common Shares
IMV
+$17.8M
5
ALXO icon
ALX Oncology
ALXO
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 86.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
26
ALX Oncology
ALXO
$261M
– –
-300,000
Closed -$11.3M
CRDF icon
27
Cardiff Oncology
CRDF
$66.5M
– –
-1,271,985
Closed -$18M
MDNA
28
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
– –
-92,453
Closed -$383K
IMV
29
DELISTED
IMV Inc. Common Shares
IMV
– –
-400,000
Closed -$17.8M
FSDC
30
DELISTED
FS Development Corp. Class A Common Stock
FSDC
– –
-500,000
Closed -$5.6M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q4 2020 Portfolio in Review

As of Q4 2020, VR Adviser held 31 positions worth $680M, up 33% from $511M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

VR Adviser deployed $61.2M of net new capital in Q4 2020, opening 9 new positions and adding to 4 existing holdings. Its largest new stake was Olema Pharmaceuticals: 1,536,193 shares worth $73.9M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 72% a quarter earlier.

On the sell side, the largest reduction was Trillium Therapeutics Inc., an estimated $45.6M trimmed.

  • VR Adviser's largest Q4 2020 buy was Olema Pharmaceuticals: 1,536,193 shares worth $73.9M.
  • VR Adviser added most to Marinus Pharmaceuticals, Inc in Q4 2020, an estimated $19.5M increase.
  • VR Adviser's biggest Q4 2020 reduction was Trillium Therapeutics Inc., cutting an estimated $45.6M.
  • VR Adviser fully exited Cardiff Oncology in Q4 2020, selling an estimated $18M.
  • VR Adviser's ten largest holdings make up 80% of its $680M portfolio in Q4 2020.
  • VR Adviser opened 9 new positions and closed 6 in Q4 2020.
  • VR Adviser's portfolio value rose 33% quarter-over-quarter to $680M.

Based on VR Adviser's 13F filing for Q4 2020, filed 12 Feb 2021.